Drug Safety in Geriatric Patients: Current Status and Proposed Way Forward
Authors:
- 4 June 2020
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 43 (9) , 853-866
Abstract
Elderly patients are the main users of drugs and they differ from younger patients. They are a heterogeneous population that cannot be defined only by age but should rather be stratified based on their frailty. The elderly have distinctive pharmacokinetic and pharmacodynamic characteristics, are frequently polymorbid, and are therefore treated with multiple drugs. They may experience adverse reactions that are difficult to recognize, since some of them present non-specific symptoms easily mistaken for geriatric conditions. Paradoxically, the elderly are underrepresented in clinical trials, especially the frail individuals whose pharmacological response and expected treatment outcome can be different from those of non-frail patients. This means that the benefit–risk balance of drugs used in frail elderly patients is frequently unknown. We present some proposals to overcome the barriers preventing the enrollment of frail elderly patients in clinical trials, and strategies for monitoring their therapy to minimize the risk of adverse reactions. Automated alerts for drug and drug–disease interactions could help appropriate prescribing but should flag only clinically relevant interactions. Pharmaceutical forms should be designed to allow easy dose adjustment and, together with packaging and labeling, should account for the physical and cognitive limitations of frail elderly patients. Aggregate pharmacovigilance reports should summarize the safety profile in the elderly, but rather than presenting the results by age they should focus on patients’ frailty, perhaps using the number of comorbidities as a proxy when information on frailty is not available.Keywords
This publication has 125 references indexed in Scilit:
- Age and Association of Kidney Measures With Mortality and End-stage Renal DiseaseJAMA, 2012
- Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trialThe Lancet, 2011
- The Frailty Syndrome: Definition and Natural HistoryClinics in Geriatric Medicine, 2011
- Adverse drug events in the outpatient setting: an 11‐year national analysisPharmacoepidemiology and Drug Safety, 2010
- Interventions to improve suboptimal prescribing in nursing homes: A narrative reviewThe American Journal of Geriatric Pharmacotherapy, 2010
- Improving Patient Understanding of Prescription Drug Label InstructionsJournal of General Internal Medicine, 2008
- Treatment of chronic inflammatory diseases with biologic agents: Opportunities and risks for the elderlyExperimental Gerontology, 2006
- Clinical Practice Guidelines and Quality of Care for Older Patients With Multiple Comorbid DiseasesJAMA, 2005
- Adherence to MedicationNew England Journal of Medicine, 2005
- Impact of inappropriate drug use among hospitalized older adultsEuropean Journal of Clinical Pharmacology, 2005